Publications

44 peer-reviewed publications, primarily in oncology: 24 are in journals with an impact factor > 5.  My current h-index is 23.

L.C Gilligan, J. Bradbury, A.E Taylor, S. He, D.M O’Neil, M. Viant, P.A Foster. A novel UPLC-MS/MS method to extract and quantify sulphated and non-sulphated oestrogens automatically optimised using MUSCLE software. J Chromatography. In preparation.

L.C. Gilligan, A-M. Hewitt, A. Kupryte, K. Burnell, D. Morton, P.A. Foster. Oestrogen metabolism is dysregulated by TNF-alpha and IL-6 in colorectal adenoma and carcinoma. Carcinogenesis. In preparation.

G. P. Prevost, S Xu, M. Garrido, M. Serova, O.D.E. Vewer, C. Gespach, J-F. Briand, A. Tijeras-Raballand, M. Gutmann, A. Hendrix, M. Sabbah, A. Chachereau, A. de Gramont, N. Neamati, M-H. Pitty, P.A. Foster. XCE853: a novel PDI inhibitor that inhibits proliferation of human tumor cells ex vivo, in vitro and in vivo. Cancer Res. In Preparation

​

Submitted/In Preparation

Published

44. P.A. Foster, J.W. Mueller. Insights into steroid sulfation and desulfation pathways. J Mol Endocrinol. 2018;[ePub ahead of print].

43. V. Chortis, A.E. Taylor, C.L. Doig, M.D. Walsh, E. Meimaridou, C. Jenkinson, G. Rodriguez-Blanco, C.L. Ronchi, A. Jafri, L.A. Metherell, D. Hebenstreit, W.B. Dunn, W. Arlt, P.A. Foster. Nicotinamide Nucleotide Transhydrogenase as a novel treatment target in adrenocortical carcinoma. Endocrinol. 2018;[ePub ahead of print]

42. D.A. Gibson, P.A. Foster, I. Simitsidellis, H. Critchley, O. Kelepouri, F. Collins, P.T. Saunders. A role for steroid sulfatase in intracrine regulation of endometrial decidualisation. J Mol Endocrinol. 2018;[ePub ahead of print]

41. W. Dohle, F.L. Jordan, G. Menchon, A.E. Prota, P.A. Foster, P. Mannion, E. Hamel, M.P.Thomas, P.G. Kasprzyk, E. Ferrandis, M.O. Steinmetz, M.P. Leese, B.V.L. Potter. Quinazolinone-based anticancer agents: Synthesisantiproliferative SAR, antitubulin activity, and tubulin co-crystal structure. J Med Chem. 2018;61:1031-1044.

40. E. Meimaridou, M. Goldsworthy, V. Chortis, E. Fragouli, P.A. Foster, W. Arlt, R. Cox, L.A. Metherell. NNT is a key regulator of adreanl redox homeostasis and steroidogenesis in male mice. J Endocrinol. 2018;236:13-28.

39. L.C. Gilligan, H.P. Rahman, A.M. Hewiit, A.J. Sitch, A. Gondal, A. Arvaniti, A.E. Taylor, M.L. Read, D.G. Morton, P.A. Foster. Estrogen activation by steroid sulfatase increases colorectal cancer proliferation via GPER. J Clin Endocrinol Metab. 2017;102:4435-4447.

38. L.C. Gilligan, A. Gondal, V. Tang, M.T. Hussain, A. Arvaniti, A.M. Hewitt, P.A. Foster. Estrone sulfate transport and steroid sulfatase activity in colorectal cancer: Implications for hormone replacement therapy. Front Pharmacol. 2017;8:103.

37. H.P. Rahman, J. Hofland, P.A. Foster. In touch with your feminine side: how oestrogen metabolism impacts prostate cancer. Endocr Relat Cancer. 2016;23:R249-66.

36. M.I. El-Gamal, M.H. Semreen, P.A. Foster, B.V.L. Potter. Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors. Bioorg Med Chem. 2016;24:2762-7.

35. J.W. Mueller, L.C. Gilligan, J. Idkowiak, W. Arlt, P.A. Foster. The regulation of steroid action by sulfation and desulfation. Endocr Rev. 2015;36:526-63.

34. C. Stengal, S.P. Newman, M.P. Leese, B.V.L. Potter, M.J.Reed, A. Purohit, P.A. Foster. The in vitro and in vivo activity of the microtubule disruptor STX140 is mediated by Hif-1 alpha and CAIX expression. Anticancer Res. 2015;35:5249-61.

33. C. Stengal, M.P. Leese, S.P. Newman, M.J. Reed, B.V. Potter, A. Purohit, P.A. Foster. STX2484, a novel tubulin binding agent, is effective against chemoresistant breast cancer. Br. J Cancer. 2014;111:300-8.

32. F. Meyer-Losic, S.P. Newman, J.M. Day, M.J. Reed, P.G. Kasprzyk, A. Purohit, P.A. Foster. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t antigen transgenic mice. PLoS One. 2013;8:e80305.

31.  P.A.Foster. Oestrogen and Colorectal Cancer: Mechanisms and Controversies. Int J Colorectal Dis. 2013;28:737-49.

30.  P.A.Foster*, J.M. Day*, H.J. Tutill, F. Schmidlin, C.M. Sharland, J.D. Hargrave, N. Vicker, B.V.L. Potter, M.J. Reed, A. Purohit. STX2171, a 17b-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocr. Relat. Cancer. 2013;20:53-64.

29. A. Purohit, P.A. Foster. Steroid sulfatase inhibitors for both estrogen- and androgen-dependent cancers. J Endocrinology. 2012;212:99-110.

28. M.P. Leese, F. Jourdan, M.R. Kimberley, G.E. Cozier, C. Stengal, S. Regis-Lydi, P.A. Foster, et al. Chimeric microtubule disruptors. Chem. Commun. (Camb.) 2010; 46:2907-9.

27.  P.A. Foster, Y.T. Ho, S.P. Newman, M.P. Leese, B.V. Potter, M.J. Reed, A. Purohit. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate surviving and XIAP expression in ovarian and prostate cancer cells. Anticancer Res. 2009; 29:3751-7.

26.  J.M. Day, P.A. Foster, H.J. Tutill, S.P. Newman, Y.T. Ho, M.P. Leese, B.V.L. Potter, M.J. Potter, A. Purohit. BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br. J. Cancer. 2009; 100:476-86.

25.  J.M. Day, A. Putohit, H.J. Tutill, P.A. Foster, L.W.L. Woo, B.V.L. Potter, M.J. Reed. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. Ann N Y Acad Sci. 2009; 1155:80-7.

24. J.M. Day, H.J. Tutill, P.A. Foster, H.V. Bailey, W.B. Heaton, C.M. Sharland, N. Vicker, B.V.L. Potter, A. Purohit, M.J. Reed. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3. Mol. Cell Endocrinol. 2009; 301:251-8.

23.  P.A. Foster, S.K. Chander, S.P. Newman, L.W.L. Woo, O.B. Sutcliffe, C. Bubert, D. Zhou, S. Chen, B.V.L. Potter, M.J. Reed, A. Purohit. A new therapeutic strategy against hormone-dependent breast cancer: The pre-clinical development of a dual aromatase and sulfatase inhibitor (DASI). Clin. Cancer Res. 2008; 14: 6469-77.

22.  S.L. Tagg, P.A.Foster, M.P.Leese, B.V.L. Potter, M.J. Reed, A. Purohit, S.P. Newman. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. Br. J. Cancer. 2008; 99:1842-8.

21.  M.F.C. Parsons, P.A. Foster, S.K. Chander, R. Jhalli, S.P. Newman, M.P. Leese, B.V.L. Potter, A. Purohit, M.J. Reed. The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer. Br. J. Cancer. 2008; 99:1433-41.

20.  P.A. Foster, M.J.Reed, A. Purohit. Recent developments of steroid sulfatase inhibitors as anti-cancer agents. Anti-cancer Agents in Med. Chem. Review. 2008; 8: 732-8.

19. P.A. Foster, S.K. Chander, M.F.C. Parsons, S.P. Newman, L.W.L.Woo, B.V.L.Potter, M.J. Reed, A. Purohit. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res. Treat. 2008; 111:129-38.

18.  P.A. Foster, Y.T. Ho, S.P. Newman, P.G. Kasprzyk, M.P. Leese, B.V.L.Potter, M.J. Reed, A. Purohit. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res. Treat. 2008; 111:251-60.

17.  P.A. Foster, L.W. Woo, B.V. Potter, M.J. Reed, A. Purohit. Steroid sulfatase inhibitors block the growth of hormone-dependent endometrial cancer xenografts: A potential new treatment. Endocinology. 2008; 149:4035-42.

16.  P.A. Foster. Steroid metabolism in breast cancer. Minerva Endocrinologica. 2008;33:27-37.

15.  P.A. Foster, S.P. Newman, M.P. Leese, S. Bernetiere, J. Camara, B.V. Potter, M.J. Reed, A. Purohit. A new micronised formulation of 2-methoxyestradiol-bis-sulphamate is therapeutically potent against breast cancer. Anti-cancer Res. 2008; 28:577-81.

14.  P.A.Foster, C. Stengal, T. Ali, M.P.Leese, B.V.L. Potter, M.J. Reed, A. Purohit, S.P. Newman. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anti-cancer Res. 2008; 28:1483-91.

13.  J.M. Day, P.A. Foster, H.J. Tutill, M.F.C. Parsons, S.K. Chander, G.M. Allan, H.R. Lawrence, N. Vicker, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo inhibition of estrone-stimulated tumor growth by STX1040; a 17b-hydroxysteroid dehydrogenase type 1 inhibitor with therapeutic potential. Int. J. Can. 2008;122:1931-1940.

12.  S.P. Newman, P.A. Foster, C. Stengel, J.M. Day, Y.T. Ho, M.P. Leese, B.V.L. Potter, M.J. Reed, A. Purohit. The orally bioavailable microtubule disruptor, STX140, is efficacious in vitro and in vivo in Taxane resistant breast carcinoma cells. Clin. Can. Res. 2008; 14:597-606.

11.  M.P. Leese, F.L. Jourdan, K. Gaukroger, M.F. Mahon, S.P. Newman, P.A. Foster, C. Stengal, S. Regis-Lydi, E Ferrandis, A.D. Fiore, G. De Simone, C.T. Supuran, A. Purohit, M.J. Reed, P.V.L. Potter. Structure-activity relationships of C-17 Cyano-substituted estratrienes as anticancer agents. J. Med. Chem. 2008; 51:1295-308.

10.  L.W. Woo, D.S. Fischer, C.M. Sharland, M. Trusselle, P.A. Foster, S.K. Chander, A. Di Fiore, C.T. Supuran, G. De Simone, A. Purohit, M.J. Reed, B.V. Potter. Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modelling, and protein crystallography. Mol. Cancer Ther. 2008; 7: 2435-44.

9.  S.P. Newman, P.A. Foster, Y.T. Ho, J.M. Day, B. Raobaikady, P.G. Kasprzyk, M.P. Leese, B.V. Potter, M.J. Reed, A. Purohit. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptos as therapy for hormone-independent prostate and breast cancer. Br. J. Cancer. 2007; 97, 1673-82.

8.  S.K. Chander, P.A. Foster, M.P. Leese, S.P. Newman, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo inhibition of angiogenesis by sulfamoylated derivatives of 2-methoxyestradiol. Br. J. Cancer. 2007; 96, 1368-76.

7.  P.A. Foster, S.P. Newman, S.K. Chander, C. Stengal, R. Jhalli, L.W.L. Woo, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin. Can. Res. 2006; 12, 5543-49.

6.  R.S. Scotland, Cohen M, P.A. Foster, M. Lovell, A. Mathur, A. Ahluwalia, A.J. Hobbs. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. PNAS. 2005; 102, 14452-7.

5.  A. Ahluwalia, P. Foster, R.A. Scotland, M.G. McLean, A. Mathur, M. Perretti, S. Moncada, A.J. Hobbs. Anti-inflammatory activity of soluble guanalyte cyclase: cyclic GMP-dependent down regulation of P-selectin expression and leukocyte recruitment. PNAS. 2004; 101, 1386-1391.

4.  A. Hobbs, P.A. Foster, C. Prescott, R. Scotland, A. Ahluwalia. Natriuretic peptide receptor-C regulates blood flow and prevents myocardial ischemia/reperfusion injury: a novel cardioprotective role for endothelium-derived C-type natiuretic peptide. Circulation 2004; 101, 1231-5.

3.  P.A. Foster, S.K.P. Costa, R. Postin, J.R.S. Hoult and S.D. Brain. Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor. FASEB. 2003; 17, 1703-5.

2.  P.A. Foster, S. Wicks, M. Foster and S.D. Brain. Cellular pathology changes in rat skin following intradermal injection of nerve growth factor (NGF): neutrophil dependent and independent events. J. Pathol. 2002; 197, 245-255.

1.  D.Q. Chu, M. Choy, P.A. Foster, T. Cao and S.D. Brain. A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin13-52 to modulate microvascular but not thermal hyperalgesia response. Br. J. Pharmacol. 2000; 130, 1589-1596.

Patents

-     Foster, P.A. Newman, S.P. Woo, L.W.L. Reed, M.J. Purohit, A. Potter, B.V.L. Treatment of oestrogen dependent condition using dual aromatase-sulphatase inhibitors (DASI). Patent pending.

-     Foster, P.A. Tagg, S.L. Newman, S.P. Reed, M.J. Purohit, A. Potter, B.V.L. Composition comprising a glycolytic inhibitor and an A-ring system comprising a sulphamate group for the treatment of cancer. U.S. Patent 20100144652. June 10, 2010.

-     Potter, B.V.L. Reed, M.J. Woo, L.W.L. Purohit, A. Foster, P.A. Steroidal compounds as steroid sulphatase inhibitors. U.S. Patent 20090182000. July 16, 2009.